German respiratory clinical research SME specializing in digital sleep diagnostics, mobility assessment, and AI-driven tools for COPD and sleep apnea.
Velocity Clinical Research Grosshansdorf is a specialist clinical research site operating in the respiratory and sleep medicine space, based near Hamburg in a region historically associated with pulmonary disease expertise. They contribute real-world patient data, clinical validation infrastructure, and site management capabilities to large multi-center research consortia. Their work spans two distinct but related domains: measuring physical function and mobility in patients with chronic conditions (COPD, Parkinson's, multiple sclerosis, hip fracture), and diagnosing and treating sleep disorders using AI-powered digital tools. As a private SME clinical research organization, they serve as the bridge between academic research protocols and actual patient populations — the kind of partner needed when a consortium must prove that a technology works in a real clinical setting.
Both MOBILISE-D and SLEEP REVOLUTION involve patient-facing clinical work in conditions (COPD, OSA, sleep-disordered breathing) consistent with a respiratory-specialist clinical site.
MOBILISE-D focused specifically on validating digital mobility assessment tools against clinical outcomes in ageing populations and chronic disease cohorts.
SLEEP REVOLUTION targets revolution of sleep diagnostics using deep learning and machine learning for personalized therapy in obstructive sleep apnea.
Participation in large multi-site RIA projects with 74 consortium partners implies structured patient recruitment, data collection, and site-level trial management across both projects.
Both projects involve validating digital diagnostics — mobility sensors in MOBILISE-D and AI-driven sleep analysis in SLEEP REVOLUTION — against regulatory and clinical endpoints.
Their first H2020 project (MOBILISE-D, 2019) placed them firmly in the digital mobility and ageing space — measuring how well patients with COPD, Parkinson's, or MS move in daily life using wearable sensors, with the goal of getting those measurements accepted as clinical trial endpoints. Their second project (SLEEP REVOLUTION, 2021) marks a pivot toward sleep medicine specifically, with a sharper focus on AI and machine learning as the enabling technology rather than just the measurement hardware. The thread connecting both is respiratory medicine: COPD appears in the first project, obstructive sleep apnea dominates the second — suggesting this organization has deep roots in pulmonology and is progressively specializing toward the sleep-disordered breathing niche where digital diagnostics and AI are converging fastest.
They are moving toward AI-driven, fully digital sleep diagnostics — a sector currently attracting significant commercial investment — and would be a natural clinical validation partner for any consortium or company developing home-based or wearable sleep monitoring technology.
They participate exclusively as consortium partners and have never coordinated a project, which positions them as specialist execution nodes rather than strategic project drivers. However, their presence in two very large RIA consortia (74 unique partners, 24 countries) shows they are trusted contributors in ambitious, well-funded research programs — not peripheral add-ons. Working with them likely means accessing a functioning clinical site with patient recruitment capability and established data collection protocols, rather than research planning or consortium management expertise.
Across just two projects, they have worked with 74 unique partners spanning 24 countries — a remarkably wide network for an SME with only two projects, indicating both MOBILISE-D and SLEEP REVOLUTION are large pan-European consortia. Their geographic reach is firmly European, with no evidence of activity beyond EU-associated countries.
Grosshansdorf is home to one of Germany's leading chest disease hospitals (LungenClinic Grosshansdorf), and this SME's location there is almost certainly not coincidental — they likely operate in close proximity to or in partnership with that clinical infrastructure, giving them access to a rare concentration of respiratory and sleep medicine patients. For any consortium needing a German clinical site with genuine respiratory patient populations and a track record in both wearable digital assessment and AI-based sleep diagnostics, they occupy a specific and hard-to-replicate niche. Their SME status also makes them eligible for SME-friendly funding instruments and gives consortia access to a more agile, commercially oriented clinical partner than a hospital department.
